Wockhardt has submitted a New Drug Application to the USFDA for its novel antibacterial agent, Zidebactam-Cefepime injection. This drug targets complicated urinary tract infections, including those caused by multidrug-resistant Gram-negative bacteria. This marks a significant milestone as the first USFDA NDA for a drug fully discovered and developed by an Indian pharmaceutical company, following successful global Phase III trials.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RVx0eK2
via IFTTT
No comments:
Post a Comment